SCHEMBL1720648

SCHEMBL1720648

Cn1nc(CN2CCC(c3ccccc3)CC2)c2c3ccccc3c(=O)[nH]c21

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 11/20 0.62
PARP2 Q9UGN5 3/20 0.49
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
DRD2 P14416 3/20 0.43
DRD4 P21917 2/20 0.43
DRD3 P35462 2/20 0.43
PARP14 Q460N5 1/20 0.42
GRM2 Q14416 1/20 0.42
HTR1A P08908 1/20 0.41
ADRA1B P35368 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CARM1 Q86X55 1/20 0.40
PRMT6 Q96LA8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1719750 0.85 PARP1 (0.56) PARP1KDM4EALDH1A1PARP14MEN1
SCHEMBL4068289 0.84 PARP1 (0.55) PARP1KDM4EALDH1A1PARP14MEN1
SCHEMBL1720862 0.84 PARP1 (0.55) PARP1PARP14
Hydrochloric Acid SCHEMBL1719747 0.83 PARP1 (0.54) PARP1KDM4EALDH1A1PARP14MEN1
SCHEMBL1720185 0.83 PARP1 (0.57) PARP1KDM4EALDH1A1PARP14MEN1
SCHEMBL1720174 0.83 PARP1 (0.57) PARP1KDM4EALDH1A1PARP14MEN1
SCHEMBL1720175 0.83 PARP1 (0.57) PARP1KDM4EALDH1A1PARP14MEN1
SCHEMBL1720808 0.83 PARP1 (0.51) PARP1KDM4EALDH1A1DRD2DRD4
SCHEMBL1720304 0.82 PARP1 (0.53) PARP1KDM4EALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL4071850 0.82 PARP1 (0.50) PARP1KDM4EALDH1A1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 PARP1 1/4885PARP2 12/4885KDM4E 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.